Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review
Authors:
- On Behalf Of The Fhu AcronimOAOn Behalf Of The Fhu Acronim
- Noémie GensousNGNoémie Gensous
- Aurélie MartiAMAurélie Marti
- Thomas BarnetcheTBThomas Barnetche
- Patrick BlancoPBPatrick Blanco
- Estibaliz LazaroELEstibaliz Lazaro
- Julien SeneschalJSJulien Seneschal
- Marie-Elise TruchetetMTMarie-Elise Truchetet
- Pierre DuffauPDPierre Duffau
- Christophe RichezCRChristophe Richez
Open Access
- 24 October 2017
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 238
Abstract
The aim of this study was to identify the most reliable biomarkers in the literature that could be used as flare predictors in systemic lupus erythematosus (SLE). A systematic review of the literature was performed using two databases (MEDLINE and EMBASE) through April 2015 and congress abstracts from the American College of Rheumatology and the European League Against Rheumatism were reviewed from 2010 to 2014. Two independent reviewers screened titles and abstracts and analysed selected papers in detail, using a specific questionnaire. Reports addressing the relationships between one or more defined biological test(s) and the occurrence of disease exacerbation were included in the systematic review. From all of the databases, 4668 records were retrieved, of which 69 studies or congress abstracts were selected for the systematic review. The performance of seven types of biomarkers performed routinely in clinical practice and nine types of novel biological markers was evaluated. Despite some encouraging results for anti-double-stranded DNA antibodies, anti-C1q antibodies, B-lymphocyte stimulator and tumour necrosis factor-like weak inducer of apoptosis, none of the biomarkers stood out from the others as a potential gold standard for flare prediction. The results were heterogeneous, and a lack of standardized data prevented us from identifying a powerful biomarker. No powerful conclusions could be drawn from this systematic review due to a lack of standardized data. Efforts should be undertaken to optimize future research on potential SLE biomarkers to develop validated candidates. Thus, we propose a standardized pattern for future studies.Keywords
This publication has 73 references indexed in Scilit:
- The complex nature of serum C3 and C4 as biomarkers of lupus renal flareLupus, 2010
- Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritisRheumatology, 2010
- Interferon‐regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation studyArthritis & Rheumatism, 2009
- Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort studyArthritis Research & Therapy, 2009
- The impact of flare on disease costs of patients with systemic lupus erythematosusArthritis Care & Research, 2009
- Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosusArthritis Research & Therapy, 2009
- Disease activity assessment in SLE: do we have the right instruments?Annals of the Rheumatic Diseases, 2007
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals of the Rheumatic Diseases, 2007
- Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flareRheumatology, 2007
- Prognostic value of anti-dsDNA in SLE.Annals of the Rheumatic Diseases, 1982